Episode 406 -- AI Risks and Compliance: Building a Governance Framework
The Briefing: Taylor Swift, Trademark Law, and the Fight Over ‘Life of a Showgirl’
DOJ’s Bulk Sensitive Data Transfer Rule: Key Insights for Health Care Compliance Teams – Diagnosing Health Care
SBR-Author’s Podcast: Bribery Beyond Borders: The Hidden History and Future of the FCPA with Severin Wirz
'Urgent National Action to Save College Sports': Trump’s NIL Playbook — Highway to NIL Podcast
March Madness or Trademark Madness? The NCAA v. DraftKings Lawsuit
Protecting Your Products and Brand Online
Lemon Pound Cake and the First Amendment
Episode 402: Paul Allen: The Promise of AI, Governance and Public Trust
Michele Moresco on the Transformational Potential of Photonics
Subject Matter Eligibility Challenges in Post-Grant Proceedings — Patents: Post-Grant Podcast
The Briefing: Vampires, Love Triangles, but No Infringement
Non-Competes in 2026: FTC Signals Major Policy Shift - Employment Law This Week® - Spilling Secrets Podcast
When Does a Beat Make You a Co-Writer? — No Infringement Intended Podcast
The Briefing: The Sound of a Lawsuit – David Greene vs Google NotebookLM
JONES DAY PRESENTS®: Trade Secret Litigation 10 Years After Enactment of the Defend Trade Secrets Act
JONES DAY TALKS®: Women in IP – Supreme Court Denies Review of Thaler v. Perlmutter: AI Authorship Questions Remain
The Briefing: No Paper, No Standing: Kanye West, Copyright Transfers, and the Writing Requirement
The Briefing: Skechers, TikTok, and Khaby Lame: Is Barrett Wissman Potentially Liable?
The LathamTECH Podcast — Trade Secrets: The New Litigation Battleground
Texas House Bill 40, passed last summer and effective as of September 1, 2025, significantly expanded the jurisdiction of the Texas Business Court – the specialized courts launched in September 2024 to handle high-stakes...more
The Federal Circuit’s decision in Teva Pharmaceuticals v. Eli Lilly & Co. (Appeal No. 24-1094) clarifies how Patent Act Section 112’s written description and enablement requirements apply to methods of using antibodies....more
In this episode of No Infringement Intended, Austin Padgett and Rusty Close unpack the half-century battle over who really owns James Bond. They trace how Ian Fleming's early collaborations fractured the rights to Thunderball...more
Artificial intelligence is rapidly transforming business operations—but it is also introducing a new generation of legal, ethical, and compliance risks. In this episode, we explore how AI risk is accelerating across...more
Can a five word phrase be worth millions? In this episode of The Briefing, Weintraub Tobin partners Scott Hervey and Matt Sugarman break down the high stakes trademark dispute between Las Vegas performer Maren Flagg and...more
A series of lawsuits highlights mounting scrutiny over AI safety and accountability. A federal suit in the Northern District of California accuses xAI of knowingly allowing its Grok chatbot to generate child sexual abuse...more
Over the past year, the U.S. Department of Justice’s (DOJ) Antitrust Division has delivered consistent message about the relationship between antitrust law and intellectual property (IP) rights: strong patent rights and...more
Few brands have matched the impact Rolex has had on the evolution of horology. From the 1926 debut of the “Oyster,”[1] the world’s first waterproof case, to the perfection of the “perpetual self-winding rotor”[2] in 1931,...more
Fortress Iron, LP v. Digger Specialties, Inc., 2026 WL 899158 (Fed. Cir. April 2, 2026) - The Constitution mandates that the U.S. patent system promote the progress of science and useful arts. Naming and crediting all...more
Today the Federal Circuit reversed a district court’s JMOL and held that claims to a method of treating headaches using a genus of antagonistic anti-CGRP antibodies satisfied both the written description and enablement...more
Pegfilgrastim Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that are filed pursuant to the Hatch-Waxman Act....more
*Etanercept Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
Tocilizumab Challenged Claim Types in IPRs: Claims are counted in each IPR, so claims from the same patent challenged in multiple IPRs are counted more than once. Within each IPR, claims are counted only once, whether they...more
From 1 April 2026, Vietnam's amended Intellectual Property Law significantly accelerates IP examination, opposition and registration timelines, while introducing new fast‑track options for qualifying applications. Although...more
Denosumab Challenged Claim Types in Litigation: Claims are counted in each litigation, so claims from the same patent challenged in multiple litigations are counted more than once. Within each litigation a claim is counted...more
Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
The U.S. Patent and Trademark Office‘s Artificial Intelligence Search Automated Pilot, or ASAP, program introduces earlier visibility into the prior art landscape by providing applicants with an automated search results...more
On April 2, 2026, the Federal Circuit Court of Appeals issued a decision in Fortress Iron, LP v. Digger Specialties, Inc. (appeal docket No. 2024-2313) that serves as a stinging reminder of the cost of incorrect inventorship....more
Regulatory Overview: Post-Approval Changes to Marketed Drugs - The popularity of GLP-1s have brought post-approval changes to New Drug Applications (NDAs) to centerstage. Recently, the FDA approved Wegovy in tablet form,...more
Our Patent Case Summaries provide a weekly summary of the precedential patent-related opinions issued by the Court of Appeals for the Federal Circuit and the opinions designated precedential or informative by the Patent Trial...more
False and misleading advertising campaigns can have significant consequences for competitors. Whether a company’s deceptive practices relate to its own products or services, a competitor’s products or services, or a...more
The U.S. Court of Appeals for the Ninth Circuit’s Jan. 2 decision in Sedlik v. Von Drachenberg — the long-running copyright dispute arising from tattoo artist Katherine Von Drachenberg’s rendering of a photograph of Miles...more
Want to learn more about drafting, negotiating, and understanding intellectual property and technology contracts and have 10 minutes to spare? Grab your morning coffee or afternoon tea and dig into our Tech Contract Quick...more
Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference product sponsors as well as...more